

Appendix 1. The quadruple-labeling antibody combinations used for MRD monitoring.

Categories	Proportion
CD2/CD56/CD45/CD3	36.1%
CD2/CD34/CD45/CD3	29.5%
CD7/CD34/CD45/CD3	14.8
CD2/CD15/CD45/CD3	9.8%
CD2/CD117/CD45/ CD3	9.8%

Appendix 2. CD34 surface expression and end of induction MRD level measured by flow cytometry



Appendix 3. The distribution of CD34 expression in different time points of MRD.

MRD	All patients n (%)	CD34 negative n (%)	CD34 positive n (%)	<i>P</i> value
MRD on day 33				
< 10 ⁻⁴	7 (8.5)	5 (9.8)	2 (6.5)	0.60
10 ⁻⁴ ~10 ⁻²	59 (72.0)	38 (74.5)	21(67.7)	
>10 ⁻²	16 (19.5)	8 (15.7)	8 (25.8)	
MRD on day 78				
<10 ⁻³	69 (93.2)	42 (91.3)	27 (96.4)	0.64
≥10 ⁻³	5 (6.8)	4 (8.7)	1 (3.6)	
Unavailable	8	5	3	

Appendix 4. EFS according to MRD level postinduction and CD34 expression status

